Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erdosteine in moderate-to-severe COPD (RESTORE)
NCT01032304Phase 3Unknown
- Sponsor
- Edmond Pharma
- Start
- Aug 2009
- Primary completion
- Mar 2014
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Erdosteine with Placebo (2 arms). Primary endpoint: Number of acute exacerbations at 12 months. Status: unknown.
02
Drugs
erdosteine
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT01032304.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01032304.